Pay in 4 interest-free payments of $6.59 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
10.1016/j.biopha.2020.110769 79 LiX.GuoL.ChenJ.LiangH.LiuY.ChenW.et al (2023)
The Oxford Centre for Evidence-Based Medicine 2011 Levels of Evidence 17 was used to grade the quality of evidence (OCEBM)
A landmark trial of more than 17,600 overweight and obese patients with cardiovascular disease (but not diabetes), found that semaglutide reduced their risk of serious cardiovascular events by 20%
Common benefits include: Significant, sustained weight loss (15-20%+ of body weight in some studies) Reduced appetite and fewer cravings Improved blood sugar control Increased energy and stamina Boosted confidence and body image Who Is a Candidate for Semaglutide Injections
